Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib

BACKGROUND. Regorafenib at the standard intermittent dosing schedule proved effective in the GRID trial for refractory gastrointestinal stromal tumors (GISTs). However, this dosing schedule requires frequent dose reduction, and the progression of GISTs or tumor‐related symptoms during the off‐treatm...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Kim, Jae‐Joon, Ryu, Min‐Hee, Yoo, Changhoon, Beck, Mo Youl, Ma, Jung Eun, Kang, Yoon‐Koo
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Sarcomas
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853125/
https://ncbi.nlm.nih.gov/pubmed/31036770
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados